Synopsis: A super-speciality hospital chain has rallied sharply over the past six months, backed by a bumper FY26, aggressive bed expansion and a marquee investor on the shareholder list. Here’s what’s driving the move.
Hospital stocks have had a mixed run this year, but one North India-focused chain has stood out. From around ₹550 in mid-January 2026 to roughly ₹850 now, the stock has delivered a sharp rally, riding on strong numbers, new hospital ramp-ups and an ambitious bed-expansion roadmap.
Shares of Yatharth Hospital & Trauma Care Services Limited. with a market capitalization of Rs.8,228 Crore, closed at Rs.851.3 i.e. around 0.69% below its previous closing price of Rs.857.2. It trades at a P/E ratio of 48.28.
A Blockbuster FY26
Yatharth Hospital & Trauma Care Services Limited closed FY26 on a strong note. Consolidated revenue for the year came in at ₹1,207 crore, up 36% year-on-year, while EBITDA rose 30% to ₹292 crore, translating into a margin of 24.2%. Profit after tax grew 30% to ₹170 crore.
The fourth quarter was even sharper, with revenue of ₹342 crore, up 47% YoY and 6% sequentially, and the company’s highest-ever quarterly EBITDA of ₹80 crore, at a margin of 23.4%. Occupancy across the network stood at 71% in Q4, while ARPOB (average revenue per operating bed) improved to ₹33,282, up 5% YoY.
The Cluster Playbook
What’s fuelling investor interest is the company’s cluster-based expansion strategy. Instead of scattering hospitals across the country, management has chosen to deepen its presence in specific micro-markets, three hospitals in Noida, two in Faridabad, and now a fresh entry into Gurugram through the acquisition of an under-construction super-speciality hospital in Sector 40.
The upfront consideration for the Gurugram asset is about ₹100 crore, with another ₹100 crore earmarked for finishing and medical infrastructure. Once operational by April 2027, management expects this hospital to command an ARPOB of more than ₹50,000, among the highest in its portfolio, given its proximity to IGI Airport and its potential to draw international and insured patients.
The company also integrated a 250-bed Agra hospital in February 2026, which is already running at an 18% EBITDA margin and generating a monthly revenue run-rate of about ₹7 crore. Newer hospitals in New Delhi and Faridabad Sector 20 together contributed around 11% of Q4 revenue and are expected to turn EBITDA-breakeven within the first half of FY27.
Balance Sheet and Bed Capacity
The company ended FY26 with a healthy cash position of ₹393 crore and a net cash position of ₹116 crore, giving it room to fund expansion largely through internal accruals rather than fresh borrowings. Total bed capacity has now crossed 3,200, and management is targeting 5,000 beds over the next three years, split roughly 70% acquisitions and 30% greenfield additions, with a possibility of hitting that target earlier than planned.
Where Mukul Agarwal and Vijay Kedia Fits In
Ace investor Mukul Mahavir Agrawal is among the prominent shareholders, having picked up a 1.14% stake in the June 2025 quarter, while Vijay Kedia bought a 1% stake via Kedia Securities Private Limited in September 2025. Together, the two have retained a combined 2.14% holding through June 2026, a period that coincides with the stock’s strong rally and adds to investor interest in the counter.
What Could Drive the Next Leg
Management has guided for FY27 revenue growth to surpass the 36% clocked in FY26, with EBITDA margins expected to stay in the 24-25% band or improve further. Tailwinds include a recent CGHS rate revision that added roughly 5% to overall revenue from Q4 FY26 onwards, a rising share of international and self-pay patients, and improving specialty mix, with oncology’s share at the Noida Extension hospital climbing from 20% to 30%.
Government-scheme patients, currently around 35% of the mix, are expected to shrink to about 25% over two years as newer hospitals skew toward private insurance and cash-paying patients.
Risks to Watch
The stock’s rally has been built on execution, but the newer hospitals in Delhi, Faridabad and Gurugram still need to prove they can scale profitably, and rising debt from the Agra acquisition has already pushed up interest costs. A pending income tax matter, which management expects to resolve by Q2 FY27, is another loose end investors will want closed out.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
